To comment scroll to the bottom of the entry. Your e-mail address and URL are optional fields. Note that the comments are moderated and will not be posted if they are not appropriate for Gagglescape readers.


Hard times for pharmaceutical industry - Canada.com

Hard times for pharmaceutical industry
Canada.com
Last month alone, Johnson & Johnson said it will close an east-end Montreal facility at the cost of 126 jobs and Sanofi Aventis announced it was cutting 100 jobs at its Canadian head office in Laval. In 2010, industry giant Merck & Co. shut its R&D ...

and more »
[email this story] Posted by R. Ouellette on 02/03 at 05:24 AM
Mapping App.
Empower your City.
Click here.

Local News
The Ottawa Business Journal has the second part of its series on startups to watch.

Chromos Molecular Systems Inc. intends to raise approximately $8 million (CDN) through a private placement of Units at a price of $0.15 per Unit.

Comnetix threatens legal action in response to Bio-key's share purchase offer.

18 proposals were received from universities and private companies in response to NanoQuébec's call for proposals for its industry-university collaborative pilot project program.

Immunotec Inc. ("Immunotec") announces that the trading of its common shares through the TSX Venture Exchange will commence at the opening of the
market on January 24, 2007, trading under the symbol "IMM".

Hy-Drive Technologies Ltd. ("Hy-Drive") (TSXV: HGS) completed the Canadian tranche of its previously announced Cdn$22.1 million private placement of approximately Cdn$11,100,000.

Duncan Hill joins Ventures West as Entrepreneur in Residence.

Acclaris, Inc., a leader in technology enabled reimbursement services for employee benefits announced that it has secured $2 million in financing from Toronto's MMV Financial Inc

February 5th, MobileMonday Toronto, the mobile industry networking group, will open the floor for prospective mobile entrepreneurs to pitch their business ideas to some of Canada's leading Venture Capital companies. The focus of this session will be raising capital for mobile ventures.

Variation Biotechnologies Inc. (VBI) announces it has secured US$35.7 million in Series A financing. VBI will use the proceeds to advance the company's innovative Variosite(TM) vaccine platform into clinical development, beginning with lead vaccine candidates for influenza.

Page 4 of 27 pages « First  <  2 3 4 5 6 >  Last »
Syndicate


Services
Stories By
Syndicate
Link Roll